These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 29602540)

  • 21. Differences in colloidal structure of PEGylated nanomaterials dictate the likelihood of accelerated blood clearance.
    Kaminskas LM; McLeod VM; Porter CJ; Boyd BJ
    J Pharm Sci; 2011 Nov; 100(11):5069-77. PubMed ID: 21721002
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation, characterization and in vivo biological activity of two distinct monoclonal anti-PEG IgMs.
    Hashimoto Y; Shimizu T; Mima Y; Abu Lila AS; Ishida T; Kiwada H
    Toxicol Appl Pharmacol; 2014 May; 277(1):30-8. PubMed ID: 24632081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes.
    Wang X; Ishida T; Kiwada H
    J Control Release; 2007 Jun; 119(2):236-44. PubMed ID: 17399838
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pegfilgrastim (PEG-G-CSF) induces anti-PEG IgM in a dose dependent manner and causes the accelerated blood clearance (ABC) phenomenon upon repeated administration in mice.
    Elsadek NE; Lila ASA; Emam SE; Shimizu T; Takata H; Ando H; Ishima Y; Ishida T
    Eur J Pharm Biopharm; 2020 Jul; 152():56-62. PubMed ID: 32376372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluating the Accelerated Blood Clearance Phenomenon of PEGylated Nanoemulsions in Rats by Intraperitoneal Administration.
    Su Y; Liu M; Liang K; Liu X; Song Y; Deng Y
    AAPS PharmSciTech; 2018 Oct; 19(7):3210-3218. PubMed ID: 30187444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Accelerated blood clearance of PEGylated liposomes containing doxorubicin upon repeated administration to dogs.
    Suzuki T; Ichihara M; Hyodo K; Yamamoto E; Ishida T; Kiwada H; Ishihara H; Kikuchi H
    Int J Pharm; 2012 Oct; 436(1-2):636-43. PubMed ID: 22850293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comprehensive analysis of PEGylated liposome-associated proteins relating to the accelerated blood clearance phenomenon by combination with shotgun analysis and conventional methods.
    Kawanishi M; Hashimoto Y; Shimizu T; Sagawa I; Ishida T; Kiwada H
    Biotechnol Appl Biochem; 2015; 62(4):547-55. PubMed ID: 25196743
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-PEG antibodies alter the mobility and biodistribution of densely PEGylated nanoparticles in mucus.
    Henry CE; Wang YY; Yang Q; Hoang T; Chattopadhyay S; Hoen T; Ensign LM; Nunn KL; Schroeder H; McCallen J; Moench T; Cone R; Roffler SR; Lai SK
    Acta Biomater; 2016 Oct; 43():61-70. PubMed ID: 27424083
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The accelerated blood clearance (ABC) phenomenon: clinical challenge and approaches to manage.
    Abu Lila AS; Kiwada H; Ishida T
    J Control Release; 2013 Nov; 172(1):38-47. PubMed ID: 23933235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A noticeable phenomenon: thiol terminal PEG enhances the immunogenicity of PEGylated emulsions injected intravenously or subcutaneously into rats.
    Wang C; Cheng X; Sui Y; Luo X; Jiang G; Wang Y; Huang Z; She Z; Deng Y
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):744-51. PubMed ID: 24129310
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Maleimide-Terminally Modified PEGylated Liposome Induced the Accelerated Blood Clearance Independent of the Production of Anti-PEG IgM Antibodies.
    Ishima Y; Yamazaki N; Chuang VTG; Shimizu T; Ando H; Ishida T
    Biol Pharm Bull; 2022; 45(10):1518-1524. PubMed ID: 36184510
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Both IgM and IgG Antibodies Against Polyethylene Glycol Can Alter the Biological Activity of Methoxy Polyethylene Glycol-Epoetin Beta in Mice.
    Chang TC; Chen BM; Lin WW; Yu PH; Chiu YW; Chen YT; Wu JY; Cheng TL; Hwang DY; Roffler AS
    Pharmaceutics; 2019 Dec; 12(1):. PubMed ID: 31877813
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A minimal physiologically based pharmacokinetic model that predicts anti-PEG IgG-mediated clearance of PEGylated drugs in human and mouse.
    McSweeney MD; Wessler T; Price LSL; Ciociola EC; Herity LB; Piscitelli JA; Zamboni WC; Forest MG; Cao Y; Lai SK
    J Control Release; 2018 Aug; 284():171-178. PubMed ID: 29879519
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polyplex-microbubble hybrids for ultrasound-guided plasmid DNA delivery to solid tumors.
    Sirsi SR; Hernandez SL; Zielinski L; Blomback H; Koubaa A; Synder M; Homma S; Kandel JJ; Yamashiro DJ; Borden MA
    J Control Release; 2012 Jan; 157(2):224-34. PubMed ID: 21945680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PEGylated nanoemulsions containing 1,2-distearoyl-sn-glycero-3-phosphoglycerol induced weakened accelerated blood clearance phenomenon.
    Li Z; Gao X; Yan X; Deng Y; Ma H
    Drug Deliv Transl Res; 2022 Oct; 12(10):2569-2579. PubMed ID: 35094294
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Polyethylene Glycol Immunogenicity: Theoretical, Clinical, and Practical Aspects of Anti-Polyethylene Glycol Antibodies.
    Chen BM; Cheng TL; Roffler SR
    ACS Nano; 2021 Sep; 15(9):14022-14048. PubMed ID: 34469112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Application of polyglycerol coating to plasmid DNA lipoplex for the evasion of the accelerated blood clearance phenomenon in nucleic acid delivery.
    Abu Lila AS; Uehara Y; Ishida T; Kiwada H
    J Pharm Sci; 2014 Feb; 103(2):557-66. PubMed ID: 24347396
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment-induced and Pre-existing Anti-peg Antibodies: Prevalence, Clinical Implications, and Future Perspectives.
    Gaballa SA; Shimizu T; Ando H; Takata H; Emam SE; Ramadan E; Naguib YW; Mady FM; Khaled KA; Ishida T
    J Pharm Sci; 2024 Mar; 113(3):555-578. PubMed ID: 37931786
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Formation of Microbubbles for Targeted Ultrasound Contrast Imaging: Practical Translation Considerations.
    Unnikrishnan S; Du Z; Diakova GB; Klibanov AL
    Langmuir; 2019 Aug; 35(31):10034-10041. PubMed ID: 30509068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using Bio-Layer Interferometry to Evaluate Anti-PEG Antibody-Mediated Complement Activation.
    Mostafa M; Elsadek NE; Emam SE; Ando H; Shimizu T; Abdelkader H; Ishima Y; Aly UF; Sarhan HA; Ishida T
    Biol Pharm Bull; 2022; 45(1):129-135. PubMed ID: 34980774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.